Hikma Pharmaceuticals PLC HKMPF
23.59 USD +0.42 (+1.80%)
At closeNov 4, 2026, 4:00 PM EST
23.00 Day range 23.00
16.34 52-week range 23.41
- YTD
- +12.63%
- 1 year
- -2.74%
- Market cap
- 4.88B
- EPS (ttm)
- 1.76
- P/E ratio
- 13.40
- YTD return
- +12.63%
- 1-year return
- -2.74%
- Volume
- 7
- Avg volume
- 464
- Open
- 23.00
- Previous close
- 23.17
- Day's range
- 23.00 – 23.00
- 52-week range
- 16.34 – 23.41
- Earnings date
- Feb 25, 2027
2Y -1.90 (-7.58%)
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 1.13.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 31, 2026 | 1.13 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 1.10 | 1.26 | +0.16 | +14.55% |
| Feb 26, 2026 | Dec 31, 2025 | 1.08 | 1.08 | 0.00 | 0.00% |
| Aug 7, 2025 | Jun 30, 2025 | 1.22 | 1.07 | -0.15 | -12.30% |
| Feb 26, 2025 | Dec 31, 2024 | — | 0.596 | — | — |
| Aug 8, 2024 | Jun 30, 2024 | — | 1.01 | — | — |
News
Hikma Pharmaceuticals Spotlights R&D Shift, Nasal Epinephrine Filing Progress 
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? 
Panmure Liberum raises Hikma target price to 1,900p 
Jefferies lifts Hikma target as CMO deal underpins growth story 
Citi sees Hikma discount as unwarranted after upgrade to forecasts 
Hikma boost as broker raises price target 
Hikma jumps 10% as brokers point to profit beat and undemanding rating 
Hikma jumps 10% as brokers point to profit beat and undemanding rating 
Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi 
Hikma recovery story still has further to run after recent rally, says Panmure
Your note
Sign in to keep a note on HKMPF — it syncs with the Stock Master app.